OverviewSuggest Edit

Saniona, a research and development company, engages in the development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The Company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trial to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of metabolic diseases and prader-wills syndromes; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase I clinical trial for ataxia/tremor.

HQBallerup, DK

Latest Updates

Employees (est.) (Feb 2019)22
Share Price (May 2020)KR27.5 (+9%)

Saniona Office Locations

Saniona has an office in Ballerup
Ballerup, DK (HQ)
154 Baltorpvej
Show all (1)

Saniona Financials and Metrics

Saniona Revenue

Market capitalization (27-May-2020)


Closing stock price (27-May-2020)

Saniona's current market capitalization is kr808.8 m.
Show all financial metrics

Saniona Online and Social Media Presence

Embed Graph

Saniona Frequently Asked Questions

  • When was Saniona founded?

    Saniona was founded in 2011.

  • How many employees does Saniona have?

    Saniona has 22 employees.

  • Who are Saniona competitors?

    Competitors of Saniona include BioSpecifics Technologies, Fibrocell Science and Gilead Sciences.

  • Where is Saniona headquarters?

    Saniona headquarters is located at 154 Baltorpvej, Ballerup.

  • Where are Saniona offices?

    Saniona has an office in Ballerup.

  • How many offices does Saniona have?

    Saniona has 1 office.